公开(公告)号：WO2020072580A1

公开(公告)日：2020-04-09

申请号：PCT/US2019/054196

申请日：2019-10-02

Applicant: DISC MEDICINE, INC.

Inventor： VENKATRAMAN, Srikanth ,  MUKHERJEE, Subhendu ,  GOSWAMI, Rajeev ,  GUMMADI, Venkateshwar Rao ,  RAJA, A. Bharathi ,  HADIANAWALA, Murtuza

IPC: A61K38/12 ,  C07K5/02

Abstract: The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.

公开(公告)号：WO2020041270A1

公开(公告)日：2020-02-27

申请号：PCT/US2019/047206

申请日：2019-08-20

Applicant: FOG PHARMACEUTICALS, INC.

Inventor： MCGEE, John, Hanney ,  THOMSON, Ty, Matthew ,  WAHL, Sebastian, Christof, Theodor ,  VERDINE, Gregory, L. ,  REZAEI ARAGHI, Raheleh ,  ZHANG, Yue-Mei ,  MULVIHILL, Mark Joseph

IPC: A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12

Abstract: The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.

公开(公告)号：WO2020023335A1

公开(公告)日：2020-01-30

申请号：PCT/US2019/042748

申请日：2019-07-22

Applicant: RUSH UNIVERSITY MEDICAL CENTER

Inventor： CHUGH, Sumant Singh

IPC: A61K9/127 ,  A61K35/16 ,  A61K38/00 ,  A61K38/04 ,  A61K38/12 ,  A61K38/16

Abstract: Described herein are methods for inhibiting the acute relapse or worsening of glomerular disease in response to viral infections associated with the common cold or flu comprising administration of anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, or blocking agents to a subject in need thereof. Also described are methods for depleting a subject's systemic levels of one or more of cytokines IL-2, IL-6, IL-10, INF-γ, or TNFα, or inhibiting the receptors IL-4R or ICAM-1 comprising contacting the cytokines or receptors with one or more anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, or blocking agents.

公开(公告)号：WO2020014652A1

公开(公告)日：2020-01-16

申请号：PCT/US2019/041674

申请日：2019-07-12

Applicant: NEW YORK UNIVERSITY

Inventor： KIRSHENBAUM, Kent ,  LOGAN, Susan ,  CRAVEN, Timothy ,  KASPER, Amanda ,  BONNEAU, Richard, A. ,  SCHNEIDER, Jeffrey, A.

IPC: A61K38/12 ,  A61K31/198 ,  A61K38/08

Abstract: Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

公开(公告)号：WO2019212377A1

公开(公告)日：2019-11-07

申请号：PCT/RU2018/000290

申请日：2018-05-04

Applicant: ФАРБЕР, Борис Славинович

Inventor： ФАРБЕР, Борис Славинович ,  МАРТЫНОВ, Артур Викторович ,  КЛЕЙН, Илья Рувимович

IPC: A61K31/714 ,  A61K38/12 ,  A61P31/04

Abstract: Изобретение относится к фармацевтическим композициям на основе полимиксина для терапии тяжелых инфекционных заболеваний. В качестве нефропротектора используют производное цианокобаламина, полученное одновременной ковалентной модификацией структуры цианокобаламина как минимум двумя модификаторами. Композицию дополняют комбинации веществ из группы: цианокобаламина, холекальциферола, викасола, пантотеновой кислоты, никотинамидидадениндинуклеотида. Фармацевтическая композиция на основе антибиотика полимиксина обладает низкой нефротоксичностью и высокой активностью в терапевтических дозах.

公开(公告)号：WO2019198090A1

公开(公告)日：2019-10-17

申请号：PCT/IL2019/050417

申请日：2019-04-12

Applicant: ARIEL SCIENTIFIC INNOVATIONS LTD. ,  HEALTH RESEARCH, INC.

Inventor： GUDKOV, Andrei ,  NESHER, Elimelech ,  PINHASOV, Albert ,  KOMAN, Igor ,  LEONOVA, Yekaterina

IPC: C07K7/64 ,  C07K7/06 ,  A61K38/12 ,  A61K38/08

Abstract: A method of treating an inflammatory disease or disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-15. The inflammatory disease is not cancer, osteoporosis, rheumatic arthritis, osteoarthritis or angiogenesis-related eye disease.

公开(公告)号：WO2019148531A1

公开(公告)日：2019-08-08

申请号：PCT/CN2018/075916

申请日：2018-02-09

Applicant: 歌礼生物科技(杭州)有限公司

Inventor： 吴劲梓 ,  古德蒙森·克里斯蒂安 ,  杨百灵 ,  单波

IPC: A61K31/4184 ,  A61K31/4709 ,  A61K38/12 ,  A61P31/14

Abstract: 本发明提供一种用于治疗丙型病毒性肝炎的药物组合物，所述药物组合物包括拉维达韦或其可药用盐(ASC16)和达诺瑞韦或其可药用盐(ASC08)。ASC16和ASC08的联合应用具有增强效应，实验结果显示ASC16与ASC08可组成有效的联合抗HCV治疗方案。而且，ASC16与ASC08联合用药方案还扩大了治疗药物的作用谱。更重要的是，二者的联用解决了耐药问题。

公开(公告)号：WO2019148067A1

公开(公告)日：2019-08-01

申请号：PCT/US2019/015348

申请日：2019-01-28

Applicant: MASSACHUSETTS EYE AND EAR INFIRMARY

Inventor： CHEN, Zheng-Yi ,  LI, Wenyan ,  QUAN, Yi-Zhou

IPC: A61K31/19 ,  A61K38/12 ,  A61K38/17 ,  A61K45/06 ,  C12N5/071 ,  C12N5/22

Abstract: Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC/NOTCH modulators, Atonal Homolog 1 (Atohl) modulators or combinations thereof.

公开(公告)号：WO2019134001A1

公开(公告)日：2019-07-04

申请号：PCT/US2018/068235

申请日：2018-12-31

Applicant: CITY OF HOPE ,  WILLIAMS, John, C. ,  BROWN, Christine ,  JENKINS, Kurt

Inventor： WILLIAMS, John, C. ,  BROWN, Christine ,  JENKINS, Kurt

IPC: A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K39/00 ,  A61K39/395 ,  A61K47/50

Abstract: Provided herein are compositions which exhibit novel therapeutic capabilities and allow to reduce the off-target effect of therapeutic antibodies. The compositions include recombinant proteins that if expressed by a T cell can efficiently recruit therapeutic antibodies to their site of action.

公开(公告)号：WO2019126341A3

公开(公告)日：2019-06-27

申请号：PCT/US2018/066529

申请日：2018-12-19

Applicant: CIDARA THERAPEUTICS, INC.

Inventor： AKERS-RODRIGUEZ, Suzanne ,  BALKOVEC, James, M. ,  BENSEN, Daniel, C. ,  BLIZZARD, Timothy ,  BORCHARDT, Allen ,  BRADY, Thomas, P. ,  CHEN, Zhi-Yong ,  DO, Quyen-Quyen, Thuy ,  DOEHRMANN, Simon ,  JIANG, Wanlong ,  LAM, Thanh ,  LEVIN, James ,  LOCKE, Jeffrey, B. ,  NONCOVICH, Alain ,  TARI, Leslie, W.

IPC: A61K38/00 ,  A61K38/04 ,  A61K38/12 ,  A61K38/14

Abstract: Compositions and methods for the treatment of bacterial infections including conjugates containing an albumin protein or an albumin protein-binding peptide covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular, conjugates can be used in the treatment of bacterial infections caused by Gram-negative bacteria.